7HD Stock Overview
Engages in the distribution of pharmaceuticals to pharmacies, hospitals, and other outpatient medical care facilities in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 7HD from our risk checks.
NEUCA S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł209.00 |
| 52 Week High | zł222.00 |
| 52 Week Low | zł135.80 |
| Beta | 0.40 |
| 11 Month Change | -2.56% |
| 3 Month Change | 4.50% |
| 1 Year Change | 19.29% |
| 33 Year Change | 19.57% |
| 5 Year Change | n/a |
| Change since IPO | 39.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7HD | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -1.5% | 0.09% |
| 1Y | 19.3% | 0.8% | 3.1% |
Return vs Industry: 7HD exceeded the German Healthcare industry which returned 0.8% over the past year.
Return vs Market: 7HD exceeded the German Market which returned 3.1% over the past year.
Price Volatility
| 7HD volatility | |
|---|---|
| 7HD Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7HD has not had significant price volatility in the past 3 months.
Volatility Over Time: 7HD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,633 | Piotr Sucharski | www.neuca.pl |
NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies, hospitals, and other outpatient medical care facilities in Poland. It operates through Pharmaceutical Wholesale, Manufacture of Pharmaceuticals, Outpatient Medical Care Clinics, Clinical Trials, and Insurance Activities segments. The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, agency, financial, road cargo transport, medical practice, software, hospital, property management, scientific research and development, and IT services; clinical and experimental development services in biotechnology; therapeutic research services for new drug and medical product developments; and health, property, and other personal insurance products.
NEUCA S.A. Fundamentals Summary
| 7HD fundamental statistics | |
|---|---|
| Market cap | €951.24m |
| Earnings (TTM) | €35.94m |
| Revenue (TTM) | €2.78b |
26.5x
P/E Ratio0.3x
P/S RatioIs 7HD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7HD income statement (TTM) | |
|---|---|
| Revenue | zł11.97b |
| Cost of Revenue | zł10.63b |
| Gross Profit | zł1.34b |
| Other Expenses | zł1.18b |
| Earnings | zł154.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 34.68 |
| Gross Margin | 11.18% |
| Net Profit Margin | 1.29% |
| Debt/Equity Ratio | 28.6% |
How did 7HD perform over the long term?
See historical performance and comparison